AC Immune

Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA (NASDAQ: ACIU), a Switzerland-based developer of advanced immunotherapies, to obtain an exclusive global license for the company’s active immunotherapies that target toxic forms of amyloid beta (Abeta). This strategic partnership positions Takeda at the forefront…